Abstract
Myelin oligodendrocyte glycoprotein associated disease (MOGAD) features may overlap with relapsing-remitting multiple sclerosis (RRMS). Little is known about brain atrophy occurrence in MOGAD. This study compares rates of brain volume change over time in MOGAD and RRMS patients.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
